Advertisement

Der Tumormarker Serotonin

  • K. Passek
  • N. Zulauf
  • M. H. Bendels
  • M. Braun
  • G. M. OremekEmail author
Übersichten: Arbeitsmedizin – Umweltmedizin

Zusammenfassung

Die vorliegende Übersicht zum Tumormarker Serotonin wird im Rahmen der Serie „Tumormarker“ des Zentralblatts für Arbeitsmedizin, Arbeitsschutz und Ergonomie publiziert, die sich mit dem immer häufigeren Gebrauch der Bestimmung von spezifischen Markern bei sog. Manager-Vorsorgen und Check-up-Untersuchungen beschäftigt. Serotonin eignet sich grundsätzlich nicht für solche Vorsorgen, sondern ist ein Marker zur Therapie‑, Verlaufs- und Rezidivkontrolle von neuroendokrinen Tumoren. Hier zeigt dieser eine hohe Sensitivität und Spezifität, wobei der Marker aber keinesfalls als Screening-Parameter zur Frühdiagnostik eingesetzt werden soll.

Schlüsselwörter

Tumormarker Serotonin Immunologische Methoden Neuroendokrine Tumoren (NET) Diagnostik 

The tumor marker serotonin

Abstract

The present overview on the tumor marker serotonin is part of the series on tumor markers of the Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, which deals with the increasing use of the determination of specific markers in so-called manager preventive and check-up examinations. In principle, serotonin is not suitable for such precautionary measures but is a marker for the treatment, progression and recurrence control of neuroendocrine tumors. In this aspect it shows a high sensitivity and specificity but the marker should not be used as a screening parameter for early diagnosis.

Keywords

Tumor marker Serotonin Immunological methods Neuroendocrine tumors (NET) Diagnostics 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

K. Passek, N. Zulauf, M.H. Bendels, M. Braun und G.M. Oremek geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Gerber A, Jäger M, Groneberg DA (2017) Editorial: Tumormarker in der Vorsorge? Zentralbl Arbeitsmed Arbeitsschutz Ergonomie 67(4):199–200CrossRefGoogle Scholar
  2. 2.
    Tsaur I, Thurn K, Juengel E, Oppermann E, Nelson K, Thomas C, Bartsch G, Oremek GM, Haferkamp A, Rubenwolf P, Blaheta RA (2016) Evaluation of TKLTL1 as a biomarker in serum of prostate cancer patients. Cent European J Urol 69(3):247–251Google Scholar
  3. 3.
    Zulauf N, Oremek GM, Groneberg D (2016) Bone marker in women with breast cancer. Curr Biomarkers 6:61–68CrossRefGoogle Scholar
  4. 4.
    Onkologie L (2018) S2k-Leitlinie Neuroendokrine Tumoren. Langversion März 2018 AWMF-Register-Nummer: 021/26Google Scholar
  5. 5.
    Bundesärztekammer (2014) Neufassung der „Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen – Rili-BÄK“. Dtsch Arztebl 111:A1583–A1618Google Scholar
  6. 6.
    Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM (2015) Validation of new cancer biomarkers: a position statement from the European group on tumor markers. Clin Chem 61(6):809–820CrossRefGoogle Scholar
  7. 7.
    Hölzel D, Schubert-Fritschle G, Schmidt M, Eckel R, Engel J (2016) Klinisch-epidemiologische Krebsregistrierung in Deutschland. Onkologe 22:61–78CrossRefGoogle Scholar
  8. 8.
    In-Vitro-Diagnostika EPURÜ (2009) Richtlinie 98/79/EG des Europäischen Parlaments und des Rates über In-vitro-DiagnostikaGoogle Scholar
  9. 9.
    Institut RK (2016) Bericht zum Krebsgeschehen in Deutschland 2016 (ICD-10 C15–26)Google Scholar
  10. 10.
    Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O’Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK (2017) The north American Neuroendocrine Tumor Society Consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 46(6):707–714CrossRefGoogle Scholar
  11. 11.
    Budnik LT, Adam B, Albin M, Banelli B, Baur X, Belpoggi F, Bolognesi C, Broberg K, Gustavsson P, Göen T, Fischer A, Jarosinska D, Manservisi F, O’Kennedy R, Øvrevik J, Paunovic E, Ritz B, Scheepers PTJ, Schlünssen V, Schwarzenbach H, Schwarze PE, Sheils O, Sigsgaard T, Van Damme K, Casteleyn L (2018) Diagnosis, monitoring and prevention of exposure-related non-communicable diseases in the living and working environment: DiMoPEx-project is designed to determine the impacts of environmental exposure on human health. J Occup Med Toxicol 13:6CrossRefGoogle Scholar
  12. 12.
    Schulte HM, Jacobeit J (2013) Lexikon der Medizinischen Laboratoriumsdiagnostik: Serotonin. Springer, Berlin, HeidelbergGoogle Scholar
  13. 13.
    Kunz PL (2015) Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol 33:1855–1863CrossRefGoogle Scholar
  14. 14.
    Bergsland EK (2013) The evolving landscape of neuroendocrine tumors. Semin Oncol 40:4–22CrossRefGoogle Scholar
  15. 15.
    Klimstra DS, Modlin IR, Coppola D et al (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39:707–712CrossRefGoogle Scholar
  16. 16.
    Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM (2013) Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol 19(47):9012–9019CrossRefGoogle Scholar
  17. 17.
    Klöppel G, Perren A, Heitz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014:13–27CrossRefGoogle Scholar
  18. 18.
    Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, Kulke M, Oeberg K, Rindi G, Sorbye H, Welin S Antibes Consensus Conference Participants (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology 105(3):196–200CrossRefGoogle Scholar
  19. 19.
    Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC (2008) Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev 17(4):959–965CrossRefGoogle Scholar
  20. 20.
    Du Y, Ter-Minassian M, Brais L, Brooks N, Waldron A, Chan JA, Lin X, Kraft P, Christiani DC, Kulke MH (2016) Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study. Endocr Relat Cancer 23(8):587–594CrossRefGoogle Scholar
  21. 21.
    Rinzivillo M, Capurso G, Campana D, Fazio N, Panzuto F, Spada F, Cicchese N, Partelli S, Tomassetti P, Falconi M, Delle Fave G (2016) Risk and protective factors for small intestine neuroendocrine tumors: a prospective case-control study. Neuroendocrinology 103(5):531–537CrossRefGoogle Scholar
  22. 22.
    Jung YS, Yun KE, Chang Y, Ryu S, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Park DI (2014) Risk factors associated with rectal neuroendocrine tumors: a cross-sectional study. Cancer Epidemiol Biomarkers Prev 23(7):1406–1413CrossRefGoogle Scholar
  23. 23.
    Romaniuk А, Lyndin M, Sikora V, Lyndina Y, Romaniuk S, Sikora K (2017) Heavy metals effect on breast cancer progression. J Occup Med Toxicol 12:32CrossRefGoogle Scholar
  24. 24.
    Westermann C, Wendeler D, Nienhaus A (2018) Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents. J Occup Med Toxicol 13:16CrossRefGoogle Scholar
  25. 25.
    Sarrouilhe D, Mesnil M (2018) Serotonin and human cancer: a critical view. Biochimie.  https://doi.org/10.1016/j.biochi.2018.06.016 Google Scholar
  26. 26.
    Modlin IM, Bodei L, Kidd M (2016) Neuroendocrine tumor biomarkers: from monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab 30(1):59–77CrossRefGoogle Scholar
  27. 27.
    Sarrouilhe D, Clarhaut J, Defamie N, Mesnil M (2015) Serotonin and cancer: what is the link? Curr Mol Med 15(1):62–77CrossRefGoogle Scholar
  28. 28.
    Joseph L, Gomes MP, Al Solaiman F, John StJ, Ozaki A, Raju M, Dhariwal M, Kim ES (2015) External validation of the HIT Expert Probability (HEP) score. Thromb Haemost 113(3):633–640CrossRefGoogle Scholar
  29. 29.
    Albert PR, Benkelfat C, Descarries L (2012) The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. Philos Trans R Soc Lond B Biol Sci 367(1601):2378–2381CrossRefGoogle Scholar
  30. 30.
    Shajib MS, Khan WI (2015) The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol (Oxf) 213(3):561–574CrossRefGoogle Scholar
  31. 31.
    Heinrich E, Trojan L, Friedrich D, Voss M, Weiss C, Michel MS, Grobholz R (2011) Neuroendocrine tumor cells in prostate cancer: evaluation of the neurosecretory products serotonin, bombesin, and gastrin—impact on angiogenesis and clinical follow-up. Prostate 71(16):1752–1758CrossRefGoogle Scholar
  32. 32.
    Fröbe A, Čičin-Šain L, Jones G, Soldič Ž, Lukač J, Bolanča A, Kusič Z (2014) Plasma free serotonin as a marker for early detection of breast cancer recurrence. Anticancer Res 34(3):1167–1169Google Scholar
  33. 33.
    Abdel-Razik A, Elhelaly R, Elzehery R, El-Diasty A, Abed S, Elhammady D, Tawfik A (2016) Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study. Eur J Gastroenterol Hepatol 28(5):599–605CrossRefGoogle Scholar
  34. 34.
    Baldo BA (2018) Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol 92(8):2457–2473CrossRefGoogle Scholar
  35. 35.
    Cheng S, Tollefson D, He G, Li Y, Guo H, Chai S, Gao F, Gao F, Han G, Ren L, Ren Y, Li J, Wang L, Varma JK, Hu D, Fan H, Zhao F, Bloss E, Wang Y, Rao CY (2018) Evaluating a framework for tuberculosis screening among healthcare workers in clinical settings, Inner Mongolia, China. J Occup Med Toxicol 13:11CrossRefGoogle Scholar
  36. 36.
    Mastrangelo G, Carta A, Arici C, Pavanello S, Porru S (2017) An etiologic prediction model incorporating biomarkers to predict the bladder cancer risk associated with occupational exposure to aromatic amines: a pilot study. J Occup Med Toxicol 12:23CrossRefGoogle Scholar
  37. 37.
    Eisenhawer C, Felten MK, Hager T, Gronostayskiy M, Bruners P, Tannapfel A, Kraus T (2017) Migrating pleural plaque in a patient with asbestos induced pleural disease: a case report. J Occup Med Toxicol 12:25CrossRefGoogle Scholar
  38. 38.
    Fuchs S, Parthier K, Wienke A, Mau W, Klement A (2017) Fostering needs assessment and access to medical rehabilitation for patients with chronic disease and endangered work ability: protocol of a multilevel evaluation on the effectiveness and efficacy of a CME intervention for general practitioners. J Occup Med Toxicol 12:21CrossRefGoogle Scholar
  39. 39.
    Alami YZ, Ghanim BT, Zyoud SH (2018) Epworth sleepiness scale in medical residents: quality of sleep and its relationship to quality of life. J Occup Med Toxicol 13:21CrossRefGoogle Scholar
  40. 40.
    Daba Wami S, Chercos DH, Dessie A, Gizaw Z, Getachew A, Hambisa T, Guadu T, Getachew D, Destaw B (2018) Cotton dust exposure and self-reported respiratory symptoms among textile factory workers in Northwest Ethiopia: a comparative cross-sectional study. J Occup Med Toxicol 13:13CrossRefGoogle Scholar
  41. 41.
    Frohlich MJ, Kroidl RF, Welte T (2018) Oxygen Consumption (V’O2) and physical Strainas measured by the occupational activity of cleaning personnel. J Occup Med Toxicol 13:4CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • K. Passek
    • 1
  • N. Zulauf
    • 1
  • M. H. Bendels
    • 1
  • M. Braun
    • 1
  • G. M. Oremek
    • 1
    Email author
  1. 1.Abt. Labordiagnostik, Institut für Arbeitsmedizin, Sozialmedizin und UmweltmedizinGoethe Universität FrankfurtFrankfurt am MainDeutschland

Personalised recommendations